Introduction {#s1}
============

In addition to amyloid plaque deposition, neuroinflammation is one of the neuropathological hallmarks of Alzheimer\'s disease (AD) (Heneka et al., [@B6]). Viral, bacterial and even fungal antigens have been found in association with the pathognomonic amyloid-beta (Aβ) depositions (Itzhaki, [@B7]; Little et al., [@B18]; Piacentini et al., [@B26]; Pisa et al., [@B27]; Zhan et al., [@B38]). The secretion of Aβ peptides during inflammation and the observation of anti-infective properties of Aβ peptides support the idea that the production of Aβ peptides provides an immune defense (Spitzer et al., [@B34], [@B33]; Condic et al., [@B4]; Kumar et al., [@B12]). These and other findings have culminated in the formulation of the infection hypothesis of AD (Miklossy, [@B23]). According to this hypothesis, amyloid deposition is the consequence of ongoing neuroinflammation evoked by a pathogen that evades the immune system.

In the diagnosis of AD, decreased levels of soluble Aβ peptide 1-42 (Aβ~1−42~) in the cerebrospinal fluid (CSF) are widely accepted as a surrogate for brain amyloidosis (McKhann et al., [@B22]; Blennow and Zetterberg, [@B3]; Jack et al., [@B8]; Lewczuk et al., [@B16]). Fitting perfectly into the infection hypothesis, reduced levels of Aβ~42~ are also found in patients with brain infections, such as bacterial meningitis, herpes encephalitis or human immunodeficiency virus (HIV)-associated dementia (Sjögren et al., [@B30]; Krut et al., [@B11]). Aβ~1−42~ is generated during cleavage of amyloid precursor protein (APP). In addition to Aβ~42~, several other Aβ peptide variants with different C- and N-termini are generated during this process (Wiltfang et al., [@B37]). It is hypothesized that it is not the overproduction of Aβ~42~ that leads to its deposition but rather an imbalance of the different Aβ peptide variants (Hasegawa et al., [@B5]; Jan et al., [@B9]). Consequently, the concentration of Aβ~1−42~ in relation to Aβ~1−40~, the most abundant Aβ peptide variant, was found to be superior to Aβ~1−42~ alone as a biomarker for AD (Lewczuk et al., [@B13], [@B14],[@B15]; Janelidze et al., [@B10]; Niemantsverdriet et al., [@B24]). If this imbalance between Aβ~42~ and Aβ~40~ that is observed in AD could also be found in inflammatory brain diseases, those data would further support the infection hypothesis of AD.

Therefore, this study investigates whether the changes in Aβ~1−42~ and Aβ~1−40~ levels in CSF during AD resemble those observed in multiple sclerosis (MS) and bacterial meningitis and whether the Aβ-ratio (Aβ~1−42~/Aβ~1−40~) differs between these diseases.

Materials and methods {#s2}
=====================

Patients
--------

Samples were collected in the memory clinic of the Department of Psychiatry, Erlangen, the Neurological Department, Erlangen, and the Neurological Department of Ludwig-Maximilian-University (LMU), Munich. Patients or their legal representatives provided their informed consent, and the study protocol was approved by the ethics committee of the University Hospital Erlangen-Nuremberg (project no. 3987) and of LMU Munich (project no. 349-15 and 174-11). Patients included in this study underwent psychiatric, neurological, medical and routine laboratory examinations. Additionally, an MRI scan and a CSF analysis were performed. The CSF of patients with meningitis was drawn under emergency conditions, so oligoclonal bands were not routinely determined. The diagnosis of AD was made according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer\'s Disease and Related Disorders Association (NINCDS-ADRDA) criteria, taking into account the Aβ~42~/Aβ~40~ ratio and the total tau and phospho-tau levels in the CSF (Albert et al., [@B1]; McKhann et al., [@B22]). The Erlangen Score (ES) algorithm (Lewczuk et al., [@B17], [@B14]) was also used to classify patients: all AD patients had an ES ≥ 3, and all controls had an ES ≤ 1. In reference to the criteria suggested by Jack et al, the patients within the AD group were classified according to the presence (+) or absence (--) of Aβ (A), neurofibrillary tangles (T) and neurodegeneration (N) as A+/T+/N+, whereas those in the control group were A--/T--/N-- (Jack et al., [@B8]). Amyloid pathology was evaluated by the Aβ~42~/Aβ~40~ ratio, tau pathology was evaluated by phospho-tau levels, and neurodegeneration was evaluated by total-tau levels and temporo-parietal atrophy in the MRI scan. Patients with intermediate signs of AD pathophysiology were excluded. MS was diagnosed according to the revised McDonald criteria (Polman et al., [@B28]), and meningitis was diagnosed according to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines (van de Beek et al., [@B36]). The control group comprised five patients with tension headache, one with schizophrenia, two with idiopathic epilepsy and one with a depressive episode. CSF samples were collected in polypropylene tubes, centrifuged within 24 h after sampling and stored in aliquots at −80°C until further use.

ELISA
-----

Aβ~1−40~ and Aβ~1−42~ levels were quantified with certified ELISA tests (IBL international GmbH, Hamburg, Germany) according to the manufacturer\'s instructions. Samples were thawed immediately before the analysis and diluted 1:20 in reagent diluent. Then, 100 μl of each sample, standard, positive control or blank were added in duplicate to a pre-coated microtiter plate. After incubation for 2 h, the plate was washed, and horseradish peroxidase (HRP)-conjugated detection antibody (clone 82E1) was added for another 1 h. After washing, the chromogenic substrate 3,3′,5,5′-tetramethylbenzidine (TMB) was added, and the plate was read. The analyses were performed under careful quality control, and a measurement was regarded as valid if the range-to-average coefficient of the duplicate measurements was below 20%.

SDS-PAGE/western blotting
-------------------------

The immunoprecipitation, urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting procedures have been described in detail before (Wiltfang et al., [@B37]; Oberstein et al., [@B25]). In short, immunoprecipitation was carried out with mouse anti-amyloid antibody 6E10 (Biolegend, formerly Covance, Koblenz, Germany), reactive to amino acids 1-16 of the Aβ peptide, covalently bound to magnetic sheep anti-mouse Dynabeads®; M-280 (10 mg/ml; Dynal, Hamburg, Germany). Samples were loaded onto bicine-SDS gels containing 8 M urea and separated for 55 min at 25 mA/gel. After semi-dry blotting onto polyvinylidene fluoride (PVDF)-membranes with a discontinuous buffer system, immunolabeling was performed with the anti Aβ~1−x~ antibody 82E1, which only recognized Aβ peptides starting with amino acid 1 (1:1,000 in phosphate-buffered saline-Tris (PBS-T); IBL, Hamburg Germany). ECL® (enhanced chemiluminescence) prime (GE Healthcare, Freiburg, Germany) was used to develop the immunoblots, and chemiluminescence was detected using an Amersham® Imager 600 instrument (GE Healthcare, Freiburg, Germany). The antibodies (6E10 for the immunoprecipitation and 82E1 for the detection) were chosen to achieve the highest possible sensitivity in this system.

Statistical analysis
--------------------

Statistical analysis was carried out with Prism® 6.0 (GraphPad Software Inc., La Jolla, CA, USA). Assuming a Gaussian distribution, parametric ANOVAs for independent samples followed by Fisher\'s *post hoc* tests were used to compare measurements among the different groups. To evaluate the diagnostic accuracy of the Aβ~1−42~/Aβ~1−40~ ratio, a receiver operating characteristic (ROC) curve was generated. Pearson\'s correlation coefficient (r) was calculated to investigate the associations between different analytes. The results are presented as the mean with standard deviations and were considered to be significant at a *p*-value \< 0.05.

Results {#s3}
=======

Study population
----------------

Samples were collected according to the same standard operating procedures at the Department of Psychiatry, Erlangen, and the Neurology Departments in Erlangen and Munich. Due to the ages at which the different pathologies typically occur, the samples could not be matched for age. However, there was no statistically significant age difference between the patients with meningitis and those with AD or between the controls and the patients with MS. The patients with meningitis had increased peripheral leucocyte counts, increased levels of C-reactive protein (CRP) and CSF protein, cells and erythrocytes and a higher CSF/serum albumin ratio. Patients with MS had slightly increased CSF leucocyte counts and positive oligoclonal bands in the CSF (Table [1](#T1){ref-type="table"}).

###### 

Patient characteristics---Patient characteristics are presented as the mean (standard deviation).

                                 **Con**         **MS**          **Meningitis**   **AD**
  ------------------------------ --------------- --------------- ---------------- ---------------
  N (female)                     9 (3)           5 (4)           9 (5)            11 (6)
  Age \[years\]                  44.1 (19.7)     36.4 (4.6)      64.8 (19.3)      69.9 (11.2)
  Blood leukocytes \[/μl\]       8.6 (4.1)       6.9 (1.6)       16.9 (7.1)       6.4 (1.7)
  Serum CRP \[mg/l\]             6.6 (13.4)      1.8 (1.3)       227.3 (100.6)    2.2 (2.4)
  OCB (+/−)                      0/9             5/0             1/2              0/11
  Total protein (CSF) \[mg/l\]   583.3 (113.9)   464.0 (166.1)   4500 (3430)      370.4 (109.7)
  Albumin ratio                  6.0 (2.2)       7.3 (2.8)       85.0 (70.0)      6.4 (2.1)
  Leukocytes (CSF) \[/μl\]       1.4 (1.3)       22.6 (14.9)     9543 (9827)      1.4 (0.9)
  Erythrocytes (CSF) \[/μl\]     5.0 (10.3)      1.5 (1.3)       1295 (2015)      11.2 (22.7)

*N, number; CON, control; MS, multiple sclerosis; AD, Alzheimer\'s disease; CRP, C-reactive protein; OCB, oligoclonal IgG bands on isoelectric focusing; CSF, cerebrospinal fluid*.

Reduced Aβ~1−42~ in AD, MS and meningitis
-----------------------------------------

All measurements were performed in the same laboratory to avoid inter-center variations. Aβ~1−40~ and Aβ~1−42~ levels were quantified by ELISA. One patient in the meningitis group had an Aβ~1−42~ concentration below the lower limit of quantification and was excluded from further analysis. As expected, a reduced concentration of Aβ~1−42~ was found in AD samples. Additionally, in MS and bacterial meningitis, concentrations of Aβ~1−42~ were reduced (Figure [1A](#F1){ref-type="fig"}). The concentration of Aβ~1−40~ also tended to be reduced in MS and meningitis but not in AD (Figure [1B](#F1){ref-type="fig"}). As a consequence, the ratio of Aβ~1−42~/Aβ~1−40~ was reduced only in AD (Figure [1C](#F1){ref-type="fig"}). No significant correlations between the increased values of erythrocytes, leukocytes or protein and the reduced concentrations of CSF Aβ~1−40~ or Aβ~1−42~ were found in patients with meningitis. The established threshold of 0.05 allowed for the differentiation of AD patient samples from control samples and samples from MS and meningitis patients with 100% sensitivity and 91% specificity.

![Different Aβ peptide profiles in AD, MS and bacterial meningitis Aβ~1−42~ **(A)** and Aβ~1−40~ **(B)** as well as the ratio (Aβ~1−42~/Aβ~1−40~) **(C)** were quantified by ELISA in the CSF of healthy controls (Con) and patients with multiple sclerosis (MS), meningitis (Men) and Alzheimer\'s disease (AD). The results are presented as the mean and standard deviation. Differences were calculated with ANOVA followed by the Fisher\'s *post hoc* test; ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001.](fnagi-10-00152-g0001){#F1}

Reduced total amyloid in MS and meningitis but not AD
-----------------------------------------------------

CSF from representative patients with bacterial meningitis, multiple sclerosis and AD as well as one control was loaded directly onto SDS gels containing 8 M urea (Figure [2A](#F2){ref-type="fig"}). To control for artificially low concentrations of Aβ peptides due to the increased protein concentrations in meningitis, an additional separation of CSF from two patients with meningitis and two controls after immunoprecipitation with the 6E10 antibody was carried out (Figure [2B](#F2){ref-type="fig"}). The detection was performed with the anti-amyloid 82E1 antibody, which is specific for Aβ~1−x~ variants.

![Reduced concentration of all Aβ peptides in bacterial meningitis **(A)** Representative SDS-PAGE/Western blots of directly loaded CSF from patients with bacterial meningitis (Men), multiple sclerosis (MS), Alzheimer\'s disease (AD) and controls (CON). **(B)** Immunoprecipitated samples from two representative patients with meningitis and two controls are depicted. The identities of the different Aβ peptide variants were defined in previous studies and are indicated on the left-hand side. Note that the longer peptides migrate below the shorter ones in this SDS-PAGE system containing urea.](fnagi-10-00152-g0002){#F2}

Reduced concentrations of all Aβ peptide variants were observed in the Western blots of CSF from meningitis patients (Figure [2](#F2){ref-type="fig"}). The concentration even dropped below the lower limit of detection.

Discussion {#s4}
==========

The concentration of Aβ~1−42~ in CSF is reduced in patients with AD, MS and bacterial meningitis. However, the ratio of Aβ~1−42~/Aβ~1−40~ is reduced only in AD, while the concentrations of all Aβ peptide variants are similarly reduced in the CSF of patients with bacterial meningitis.

This is the first study to show the distinct changes in Aβ peptide variants in the CSF during AD compared to inflammatory brain diseases.

Nevertheless, the study has several limitations. The sample size is relatively small, and an exact matching of age and sex was not possible. Sample matching is nearly impossible for age because AD is usually diagnosed above the age of 60, while patients with MS become symptomatic before the age of 50. However, the CSF concentrations of Aβ peptides have been reported to be relatively stable throughout life and to be independent of sex in healthy subjects (Resnick et al., [@B29]).

To reduce the possible center effects, a balanced composition of the control and the meningitis groups was achieved. However, the samples for the MS group were all collected in Munich, while the samples for the AD group were all collected in Erlangen. However, the preanalytical handling of the samples was identical at all sites, and measurement of the Aβ peptides by ELISA was carried out in a single laboratory, as was recommended to effectively reduce center effects (Mattsson et al., [@B20]).

While Aβ~1−42~ is reduced in all three diseases, the observation that the Aβ ratio is reduced in AD but not in meningitis or MS points to a better diagnostic performance of the Aβ ratio. This improved performance has also been previously shown for the differential diagnosis of AD vs. non-neurodegenerative neuropsychiatric diseases, Lewy-body dementia, Parkinson\'s disease dementia or vascular dementia (Lewczuk et al., [@B15]; Janelidze et al., [@B10]). Several others have therefore suggested to replace the measurement of Aβ~1−42~ with the Aβ ratio for AD diagnosis (Blennow and Zetterberg, [@B3]). Our study suggests that the Aβ ratio not only is able to increase the diagnostic performance in the differential diagnosis of neurodegenerative diseases but also helps to differentiate AD from neuroinflammatory diseases.

In the context of the infection hypothesis of AD, the observed differences among AD, MS and meningitis point to different pathophysiological processes behind the changes in CSF Aβ~1−42~ concentrations. While the processing of APP in AD is changed in a way that leads to an imbalance between the different Aβ peptide variants and allows the accumulation of Aβ~1−42~ into amyloid plaques, it was hypothesized that APP processing is impeded during CNS infections (Krut et al., [@B11]). Reduced concentrations of secreted (s)APPα and sAPPβ during meningitis support this interpretation (Krut et al., [@B11]). An alternative explanation is that serum proteins entering the CSF after breakdown of the blood brain barrier in meningitis might mask the detection of Aβ peptides. However, others have found no differences in Aβ peptide concentrations via ELISA after adding proteins to the CSF (Bjerke et al., [@B2]), and our data show no correlation between increased CSF protein concentrations and reduced concentrations of Aβ peptides. Additionally, we performed immunoprecipitation to release the Aβ peptides from their protein bonds. We suggest that the amyloid peptides build complexes around the invading pathogens and are therefore no longer measurable in the CSF (Spitzer et al., [@B33]). By agglutinating microorganisms and exerting a direct antimicrobial activity, Aβ peptides have been shown to accumulate around microorganisms *in vitro* (Soscia et al., [@B32]; Torrent et al., [@B35]; Kumar et al., [@B12]; Spitzer et al., [@B33]). The increased expression and distinct processing of APP during immunological activation *in vitro* also favors the idea of an immunological function and an increased consumption of Aβ peptides during infections and neuroinflammation in MS (Maler et al., [@B19]; Sondag and Combs, [@B31]; Spitzer et al., [@B34]). Further research is necessary to analyze the composition and fate of the Aβ peptides accumulating around the invading pathogens.

Current knowledge of inflammation-induced changes in Aβ peptide metabolism is mainly based on studies of acute infections (Spitzer et al., [@B34]; Kumar et al., [@B12]). Although MS is not an infectious disease, we used samples from MS patients to investigate the Aβ peptide levels in a chronic inflammatory disease. Mattsson and his colleagues measured the levels of Aβ~38~, Aβ~40~, and Aβ~42~ in patients with chronic neuroborreliosis (Mattsson et al., [@B21]). In both studies investigating two different entities causing chronic neuroinflammation, the concentrations of all measured Aβ peptide variants were reduced (Mattsson et al., [@B21]). Therefore, it seems that chronic neuroinfection and neuroinflammation are also associated with reduced levels of all Aβ peptides.

Taken together, the results of this study point to different mechanisms resulting in reduced Aβ~1−42~ levels in the CSF of patients with AD, bacterial meningitis or MS. The Aβ~1−42~/Aβ~1−40~ ratio may help to distinguish AD from neuroinflammatory diseases. Further studies are needed to confirm these findings.
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